Table 2 Reasons for discontinuation of standard IFN therapy (n=10)
| Â | Age | Sex | Liver disases | Extrahepatic manifestations | HCV genotype | HCV RNA level | Course of IFN therapy | Reasons for discontinuation of IFN therapy | Effect of IFN therapy |
|---|---|---|---|---|---|---|---|---|---|
Group 1-A with intake of Aminofeel (n=4) | 70 | F | LC-C & post HCV-related HCC | None | 1b | High | Peg-IFN alpha 2b/RBV | Encephalopathy | Non-SVR |
| Â | 67 | F | CH-C | Hypertenstion, hyperlipidemia, and hypothyroidism | 1b | High | Peg-IFN alpha 2b/RBV | Exacerbation of hypothyroidism | Non-SVR |
| Â | 58 | F | CH-C | Diabetes mellitus and hypertenstion | 1b | High | Peg-IFN alpha 2b/RBV | Fundal hemorrhage | Non-SVR |
| Â | 66 | M | CH-C | Diabetes mellitus | 1b | High | Peg-IFN alpha 2b/RBV | Increased transaminase | Non-SVR |
Group 1-B without intake of Aminofeel (n=6) | 65 | F | CH-C | None | 1b | High | Peg-IFN alpha 2b/RBV | Increased HCV RNA levels | Non-SVR |
| Â | 26 | F | CH-C | None | 2a | High | Peg-IFN alpha 2b/RBV | Relocation | SVR |
| Â | 65 | F | CH-C | Hypertenstion | 1b | High | Peg-IFN alpha 2b/RBV | Pneumonia | Non-SVR |
| Â | 59 | F | CH-C | Hypertenstion | 1b | High | Peg IFN alpha 2a monotherapy - (change) - Peg-IFN alpha 2a/RBV | Increased HCV RNA levels | Non-SVR |
| Â | 54 | M | CH-C | Diabetes mellitus | 2a | Low | Peg-IFN alpha 2a monotherapy | Anorexia | SVR |
| Â | 64 | M | CH-C | None | 1b | High | Peg-IFN alpha 2b/RBV | Arthralgia and sleeplessness | SVR |